Sarepta Therapeutics shared preliminary clinical data that lifted sentiment around its next wave of RNA-based muscle disease programs, including SRP-1001 and SRP-1003. The company reported early evidence of safety and potential efficacy as it works to rebuild after setbacks around its Duchenne muscular dystrophy franchise. Separately, Sarepta also posted early success on Arrowhead Pharmaceuticals’ RNAi assets, adding another early dataset to its RNA strategy. Taken together, the updates suggest Sarepta is using multiple RNA modalities to hedge clinical risk and extend its runway in muscular dystrophy and related rare neuromuscular indications. Investors will watch for confirmatory updates later this year and pivotal timing in 2027, with the near-term goal being clearer differentiation versus prior RNA gene-therapy expectations and the ability to generate durable clinical signals.